Drug Profile

Enbezotinib - Turning Point Therapeutics

Alternative Names: RET/SRC kinase inhibitor - Turning Point Therapeutics; TPX-0046

Latest Information Update: 30 Jun 2023

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Turning Point Therapeutics
Class Antineoplastics; Macrocyclic compounds; Small molecules
Mechanism of Action Proto-oncogene protein c-ret inhibitors; Src-family kinase inhibitors

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

Highest Development Phases

Discontinued Solid tumours

Most Recent Events

18 Jun 2023 Discontinued - Phase-I/II for Solid tumours (Late-stage disease, Metastatic disease) in South Korea (PO)
18 Jun 2023 Discontinued - Phase-I/II for Solid tumours (Late-stage disease, Metastatic disease) in USA (PO)
19 May 2023 Chemical structure information added

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com